Recently, the State Administration for Market Regulation issued the "Compliance Guidelines for Pharmaceutical Enterprises to Prevent Commercial Bribery Risks" (hereinafter referred to as the "Guidelines"). The "Guidelines" closely align with the realities of the pharmaceutical industry, focusing on concrete descriptions and practical guidance. It summarizes and organizes commercial bribery risk points in 9 specific scenarios: academic visits and exchanges, business receptions, Consulting Services, outsourcing services, discounts and commissions, donations and sponsorships, the provision of Medical Devices for free, clinical research, and retail terminal sales, covering the entire business process in the pharmaceutical purchasing and sales field. Based on guiding pharmaceutical enterprises to accurately identify, assess, and classify commercial bribery risks, it proposes classified handling plans for these risks, guiding enterprises to fully play their primary role and effectively enhance the initiative and effectiveness of compliance management.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
Trump will return to the White House next week! What are the important processes for the inauguration ceremony? Please keep this observation and Trade guide.
AI demand has once again been proven! Taiwan Semiconductor's Q4 net profit increased by 57% year-on-year, exceeding expectations, with gross margin rising to 59%.
Taiwan Semiconductor's stock price is nearing a historical high! The "King of Asia's Stocks" exceeded expectations in Q4 performance, driving the Semiconductors Sector to collectively strengthen.
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
反医药企业商业贿赂 市场监管总局出台指引
Against commercial bribery in the pharmaceutical industry, the State Administration for Market Regulation has issued guidelines.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report